Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8335438 | 0.91 | GSK3B (0.51) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL13411617 | 0.90 | GSK3B (0.58) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2851249 | 0.90 | GSK3B (0.61) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8334536 | 0.90 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8334540 | 0.90 | GSK3B (0.50) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2851122 | 0.89 | GSK3B (0.59) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2859061 | 0.89 | GSK3B (0.53) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8337384 | 0.89 | GSK3B (0.53) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8334184 | 0.89 | GSK3B (0.58) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2852846 | 0.88 | GSK3B (0.60) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | claimed |
| CN-1726209-B | 3-substituted-4-pyrimidone derivatives | SANOFI AVENTIS | 2011-04-13 | — | — | CN | claimed |
| US-7683069-B2 | 3-substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-23 | — | — | US | claimed |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORPORATION OF OSAKA JAPAN | 2007-06-21 | — | — | US | claimed |
| CN-1726209-A | 3-substituted-4-pyrimidone derivatives | SANOFI AVENTIS (JP) | 2006-01-25 | — | — | CN | claimed |
| EP-1572681-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2005-09-14 | — | — | EP | claimed |
| WO-2004055007-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | WO | claimed |
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | disclosed |
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-7683069-B2 | 3-substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7683069-B2 | 3-substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7683069-B2 | 3-substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORPORATION OF OSAKA JAPAN | 2007-06-21 | — | — | US | disclosed |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORPORATION OF OSAKA JAPAN | 2007-06-21 | — | — | US | disclosed |
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORPORATION OF OSAKA JAPAN | 2007-06-21 | — | — | US | disclosed |
| WO-2004055007-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142409-A1 | 3-Substituted-4-pyrimidone derivatives | TTBK1, MAPT, TTBK2 | GSK3B 129/4885CYP1A2 2560/4885CYP2D6 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.